ReviewPathology international2025
A Novel Tight Junction-Nuclear Receptor Signaling Pathway Regulating Cancer Progression.
Review in Pathology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nuclear receptors (NRs) are lipid ligand-binding transcription factors, with 48 members having been identified in humans to date. They are involved in diverse physiological processes, including development and homeostasis, and are also implicated in the pathogenesis of various diseases, most notably cancer. While NR activity is primarily regulated by specific ligand binding, posttranslational modifications, particularly phosphorylation, also play a critical role in modulating their function. Recently, we identified a novel signaling pathway linking claudins (CLDNs), cell-cell adhesion proteins, to NRs. CLDN-mediated cell-cell adhesion activates Src family kinases (SFKs), leading to serine phosphorylation of several NRs. This newly-discovered CLDN-NR pathway contributes to epithelial differentiation in stem cells and promotes cancer progression. In this review, we discuss the biological significance and underlying mechanisms of this, tracing the development of our research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.